Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
Oversold health care stocks Align Technology, Dianthus Therapeutics and Ocular Therapeutix show RSI readings near or below 30, signaling potential value.
Stocks · News reference
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $122
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $105 to $122.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics granted equity awards to six newly-hired, non-executive employees on October 1, 2026. The inducement grants consist of non-qualified stock options to purchase 106,000 shares of common stock with an exercise price of $88.32 per share and a 10-year term, vesting 25% after one year followed by equal monthly installments over 36 months.
Dianthus Therapeutics Files Automatic Mixed Shelf Registration; Size Not Disclosed
This Shopify Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Wall Street analysts initiated coverage on PPG, Shopify, Chesapeake Utilities, Global Payments and Dianthus, with targets ranging from $101 to $160.